Heron Therapeutics (HRTX) Share-based Compensation (2010 - 2026)
Heron Therapeutics' (HRTX) quarterly Share-based Compensation came in at $29.3 million in Q1 2026, up 45681.25% YoY from N/an in Q1 2025, and up 1244.65% on a QoQ basis from $2.2 million in Q4 2025.
Heron Therapeutics (HRTX) Share-based Compensation (2010 - 2026) Analysis & Trends
Heron Therapeutics (HRTX) has 17 years of Share-based Compensation data on file, last reported at $29.3 million in Q1 2026.
- Quarterly Share-based Compensation rose 45681.25% year-over-year to $29.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.3 million (up 442.69% YoY) and the FY2025 annual result came in at $22.0 million, up 11.11% from the prior year.
- Share-based Compensation advanced to $29.3 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $29.3 million in Q1 2026 to a low of -$637000.0 in Q1 2022.
- A 5-year average of $4.4 million and a median of $194000.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 325.0% — and 2026, when it soared 45681.25%.
- Tracing HRTX's Share-based Compensation over 5 years: stood at $10.5 million in 2022, then plunged by 58.87% to $4.3 million in 2023, then sank by 46.92% to $2.3 million in 2024, then decreased by 5.05% to $2.2 million in 2025, then soared by 1244.65% to $29.3 million in 2026.
- The last three Share-based Compensation figures came in at $29.3 million (Q1 2026), $2.2 million (Q4 2025), and $24.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Heron Therapeutics | 58.32 Mn | 15.65 Mn | 26.09 Mn | 26.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.20 Mn |
| Jun 30, 2026 | 26.20 Mn |
| Mar 31, 2026 | 29.30 Mn |
| Mar 31, 2026 | 29.30 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Sep 30, 2025 | 24.40 Mn |
| Sep 30, 2025 | 24.40 Mn |
| Jun 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 194,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Mar 31, 2025 | 64,000.00 |
| Dec 31, 2024 | 2.30 Mn |
| Dec 31, 2024 | 2.30 Mn |
| Sep 30, 2024 | 2.72 Mn |
| Sep 30, 2024 | 2.72 Mn |
| Jun 30, 2024 | 318,000.00 |
| Jun 30, 2024 | 318,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |